Q-omics provides the consensus-scored PPFIA4 profile across patient tissues and cancer cell-line models. PPFIA4 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, PPFIA4 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, PPFIA4 RNA expression shows 19,532 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight COAD, KIRC, and UVM as cancer lineages where PPFIA4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPFIA4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPFIA4 survival associations across molecular data types. PPFIA4 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPFIA4 RNA expression–survival associations across cancer types. High PPFIA4 expression shows unfavorable associations in COAD, KICH, ACC, LIHC, KIRP and THYM. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for PPFIA4 RNA expression.
This table summarizes PPFIA4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PPFIA4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPFIA4 shows lower tumor expression in KICH and higher tumor expression in KIRC, COAD, BLCA, LUAD and UCEC. The KIRC box plot shows higher PPFIA4 RNA expression in tumor versus normal tissue (log2 FC = +1.809, t-test p < 0.001).
This table shows molecular features associated with PPFIA4 in patient tissues and cancer cell lines. In patient samples, PPFIA4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PPFIA4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and SKIN.
